Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF
Rahul R. Aggarwal, Tomasz M. Beer, Vivian K. Weinberg, Celestia Higano, Mary Ellen Taplin, Charles J. Ryan, Amy M. Lin, Joshi Alumkal, Julie N. Graff, Luke T. Nordquist, Isheen Herrera, Eric J. Small
Dive into the research topics of 'Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF'. Together they form a unique fingerprint.